Source Photonics Announces New 100G ZR4 QSFP28 Transceiver for Data Center Interconnects and Routing Applications
7.12.2020 17:31:00 EET | Business Wire | Press release
Source Photonics, a leading vendor of optical connectivity products used in telecommunication systems and data communications networks, today announces the release of its new 100G ZR4 QSFP28 transceiver for 80km high-speed data center interconnects and routing applications. Leveraging the widely deployed 4 x 25G NRZ optics, 100G ZR4 QSFP28 is the latest addition to the company’s dominant 100G product lines among its leading 100/200/400G portfolio of single-mode transceivers for datacenter and routing applications.
Cloud traffic continues to drive data center growth and the industry requires cost-effective and high-bandwidth interoperable solutions. The Source Photonics 100G ZR4 QSFP28 is cost optimized and low power transceiver supporting 100G Ethernet for extended reach up to 80km transmission that provides point to point network connectivity solutions between data centers or central offices without the need to deploy either complicated, power hungry, and expensive coherent solution or legacy CFP/CFP2 interfaces. The 100G ZR4 QSFP28 alleviates the fiber shortage bottlenecks and enables hyperscale cloud operators to scale their network.
The transceiver is in QSFP28 form factor, the smallest for 100G 80km solution. It is fully compliant with the industry standard QSFP28 and related MSA described in the latest SFF-8665/8636 and digital diagnostic functions are available through an I2C interface. It also complies with IEEE 802.3 100GBASE-ZR4 related specifications. In addition, the module supports standard KR4 FEC (Forward Error Correction) baud rates which will help receive side detect and correct bit errors and improve the overall quality of the link. The 100G ZR4 QSFP28 transceiver is capable to operate over up to 80km point-to-point link without the need for optical amplification and dispersion compensation.
Source Photonics will showcase a product demonstration of the 100G ZR4 QSFP28 transceiver for 80km optical transmission in its virtual booth, in addition to live booth activities, and informative video content during the ECOC 2020 Virtual Exhibition on December 7 to 9.
Source Photonics is currently sampling its 100G ZR4 QSFP28 product, in addition to its latest 100G ER4 and 400G ER8 transceivers. Source Photonics is in full production of its other products for data center and routing applications such as 100G LR4/ER4 Lite, 100G DR1/FR1/LR1, and 400G DR4/FR4/LR4/LR8 transceivers.
For more information about Source Photonics and its product offering, please visit www.sourcephotonics.com.
About Source Photonics:
Source Photonics is a leading provider of innovative and reliable optical communications technology that enables communications and connectivity in datacenters, metro, and access networks. We add value to our customers by developing next-generation solutions that enable their growth by meeting the rapidly increasing demands of cloud infrastructure, wireless communications, routing, and fiber-to-the-premises applications worldwide. Source Photonics has key R&D and manufacturing facilities in California, Taiwan, Chengdu, and Jintan, China.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201207005591/en/
Contact information
Media Contact:
Jasmin Basal
Director, Sales and Marketing
Phone: 818-885-4202
Email: jasmin.basa@sourcephotonics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom